NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

'OLAP' (OLAparib Regulatory Post-marketing Surveillance)

CompletedN/A

Sponsor: AstraZeneca

Conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer

Countries: South Korea

The objectives of this study are to assess safety and effectiveness of Lynparza tablet (olaparib, hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug according to the approved indications in South Korea

Eligibility overview

Sex: ALL

Age: 19 Years to 150 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Eligible for the study drug treatment according to the approved label in South Korea
2. Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion Criteria:

1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug
2. Prior exposure to any Polyadenosine 5'diphosphoribose polymerase (PARP) inhibitors, including the study drug
3. Pregnant and/or breast feeding
4. Current participation in any interventional trial
5. Other off-label indications according to the approved label

Locations (18)

Ansan, South Korea
Bucheon-si, South Korea
Busan, South Korea
Changwon, South Korea
Daegu, South Korea
Daejeon, South Korea
Goyang, South Korea
Gunpo, South Korea
Hwaseong, South Korea
Ilsan, South Korea
Incheon, South Korea
Jeonju, South Korea
Seongnam, South Korea
Seoul, South Korea
Suwon, South Korea
Uijeongbu-si, South Korea
Yangsan, South Korea
Yongin, South Korea